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Overview of Epidemiological study 
Designs
Richard Ssekitoleko
Department of Global Health
Yale University
Objectives
• Understand the different epidemiological study types
• Get to know what is involved in each type of study
• Understand the strengths and Limitations of each study type
Key terms
• Population
• Consists of all elements and is the group from which a sample is drawn
• A sample is a subset of a population
• Parameters
• Summary data from a population
• Statistics
• Summary data from a sample
• Validity
• Extent to which a conclusion or statistic is well-founded and likely corresponds 
accurately to the parameter.
Hierarchy of Evidence
Study type
Observational Interventional
Descriptive Experiment
Ecological Randomized Controlled Trial
Cross-sectional
Case-control
Cohort
Overview of Epidemiologic Study 
Designs
Validity
Cost*anecdotes
Understanding What Physicians Mean:
In my experience … once.
In case after case … twice.
It is believed that …I  think.
It is generally believed that … a couple of other guys think 
so too.
In a series of cases … thrice.
Epidemiologic Study Designs
Validity
Cost*anecdotes
*case series
Case Series
• Physicians report on a series of cases and make inference about 
causation.
• Have a denominator of only one or a small number of cases.
• No comparison arm
• Hypothesis development
Case series
• Dr. McBride, an experienced 
obstetrician in Australia, saw 
four babies with very rare limb 
deformities.  
• Each of the mothers had taken 
thalidomide during pregnancy.
Case series
• This case series study worked. Eventually he found 9 cases, 
and thalidomide had been used in specific weeks of 
pregnancy
• Case series sometimes work. The disease must normally be 
very rare, and the relationship with exposure very strong 
• Recent case series on dolutegravir and neuro tube defects 
in Botswana.
Distinguishing study Designs
• In a case series:
• Data is available on only those with the outcome( The cases)
• Inference is based on some characteristic (“exposure”) being unusual (usually 
thought to be rare except in the cases).
Epidemiologic Study Designs
Validity
Cost*anecdotes
*case series
*ecological study
Study designs
• Ecological study design
• The unit of analysis is the group as opposed to the individual
• There is no data on exposure status and outcome for each individual in it.
• Susceptible to the ecological fallacy
Ecological study
• Study in which units of analysis are 
populations rather than individuals
Strengths
• Exposure data often only available at area level.
• Differences in exposure between areas may be bigger than at the individual 
level, and so are more easily examined.
• Utilization of geographical information systems to examine spatial framework 
of disease and exposure.
• Limitations
• Measures of exposure are only a proxy based on the average in the 
population. (ecological fallacy).
• Potential for systematic differences between areas in recording disease 
frequency. For example there may be differences in disease coding and 
classification, diagnosis and completeness of reporting between different 
countries.
• Potential for systematic differences between areas in the measurement of 
exposures.
• Lack of available data on confounding factors.
Epidemiologic Study Designs
Validity
Cost*anecdotes
*case series
*ecological study
*cross-sectional study
Cross sectional studies
• May also be a prevalence survey
• Exposure and disease status are 
assessed simultaneously among 
individuals in a well defined 
population
Cross-sectional Studies
• Measure the prevalence of disease in a population at a snap shot 
moment
• Measure the true burden of disease in a population as:
• they usually obtain more accurate information than routinely collected 
data
• they detect cases which have not presented to medical care (clinical 
iceberg)
• Comparison of exposed group to 
unexposed group regarding outcome.
• Temporal ordering not clear
• Used to generate relations between 
exposure and outcomes and to 
generate hypotheses.
• Length biased sampling: Cases with 
long duration are over represented.
• Strengths
• Used to prove and/or disprove assumptions
• Not costly to perform and does not require a lot of time
• Captures a specific point in time
• Contains multiple variables at the time of the data snapshot
• The data can be used for various types of research
• Many findings and outcomes can be analyzed to create new theories/studies 
or in-depth research
• Limitations
• Cannot be used to analyze behavior over a period to time
• Does not help determine cause and effect
• The timing of the snapshot is not guaranteed to be representative
• Findings can be flawed or skewed if there is a conflict of interest with the 
funding source
Epidemiologic Study Designs
Validity
Cost*anecdotes
*case series
*ecological study
*cross-sectional study
*case control study
STUDY DESIGNS
CASE-CONTROL STUDIES
Study in which you select cases with a disease and 
compare their past exposures with a selected group of 
non-cases (controls).
Case-control study
• Type of observational study
• Groups for comparison defined by whether they;
• Have disease or outcome of interest (a case)
• Do not have disease or outcome of interest (a control)
• Intuitively obvious and deceptively simple design - extension of clinical history
• Sampling in case control studies
• Risk set sampling
• Cumulative based sampling
• Case cohort sampling
Case-control study
Cases
Controls
Past exposures Current outcome
DISTINGUISHING STUDY DESIGNS
CASE-CONTROL STUDIES:
Start by identifying cases with the disease.
Case definition
• Pathological - histological diagnosis of breast cancer
• Radiological - CT scan of a brain tumour
• Microbiological - Sputum positive TB
• Clinical - Parkinson’s disease diagnosed by neurologist.
• Self-report - GHQ depression
The controls
• Are not what you might think they are. Unlike the usual use of the 
term, they are NOT a group without exposure.
• Should be representative of the source population in which the 
cases occurred (in particular with regard to exposure).
• Do not get controls based on exposure status
• Strengths
• They are efficient for rare diseases or diseases with a long latency period 
between exposure and disease manifestation.
• They are less costly and less time-consuming
• Good for dynamic populations in which follow-up is difficult.
• Limitations
• They are subject to selection bias.
• They are inefficient for rare exposures.
• Information on exposure is subject to observation bias.
• They generally do not allow calculation of incidence (absolute risk).
Epidemiologic Study Designs
Validity
Cost*anecdotes
*case series
*ecological study
*cross-sectional study
*case control study
*nested case-control study
*retrospective cohort study
*prospective cohort study
STUDY DESIGNS
COHORT STUDIES
Study in which you follow a group of people (the cohort) over time to 
find out how their exposure relates to the occurrence of health 
outcomes.
DISTINGUISHING STUDY DESIGNS
COHORT STUDIES:
• Start by identifying an “exposed and unexposed” population group before 
disease occurs.
• Prospective cohort study: you identify the exposed and unexposed population 
now and follow them for outcomes into the future
• Retrospective (historical) cohort study: Identify a population in the past and find 
out what has happened to them up to the present with regards to an exposure.
Cohort Study
• Cohort studies are a type of observational study
• For a cohort study 
• Start with a random sample of the target population (just like a cross-sectional 
study)
• Establish the exposure status (Exposed or unexposed)
• Follow-up over time to identify incident cases of disease (outcome)
• Compare risk of becoming an incident case in those exposed at baseline 
compared to those who are not exposed
1.33
7.34
Main Features of a Cohort Study
Subset of defined population (cohort) 
recruited
Exposure to defined factors measured at 
baseline
Risk ratio
calculated
Follow up to record new 
episodes of outcome(s) of interest
• Strengths
• Clarity of temporal sequence
• Allow calculation on incidence
• Facilitate study of rare exposures
• Allow study of multiple effects of a single exposure
• Avoid selection bias at enrolment
• Limitations
• You may have to follow large numbers of subjects for a long time.
• Expensive and time consuming.
• Not good for rare diseases.
• Not good for diseases with a long latency.
• Differential loss to follow up can introduce bias.
DISTINGUISHING STUDY DESIGNS
ECOLOGIC STUDIES
No individual link between exposure and outcome. Unit of measure is the group
CROSS-SECTIONAL STUDIES:
Identify exposure and disease in a population at the same time.
CASE-CONTROL STUDIES:
Start by identifying cases with the disease, get controls and asses for past 
exposure.
COHORT STUDIES:
Start by identifying an “exposed” population group before disease occurs.
Sources of Exposure and Outcome Data
Exposure data
• Medical records
• Employment records
• Interviews
• Questionnaires
• Medical tests
• Environmental tests
etc.
Outcome data
• Medical records
• Death certificates
• Physical examination
• Questionnaires
etc.
The 3C Study Types
retrospective
cohort study
time 
study 
commences
exposure outcomes prospective
cohort study
exposure outcomes
exposure
cases with 
outcome
controls with
no outcome
COHORT
CASE-CONTROL
CROSS-SECTIONAL
exposure outcome
Note: in each of the 3C designs, individuals are either exposed or not exposed.  The use of 
individual data contrasts with ecological studies which are based on group data, usually 
dependent on geographic location.
Epidemiologic Study Designs
Validity
Cost*anecdotes
*case series
*ecological study
*cross-sectional study
*case control study
*nested case-control study
*retrospective cohort study
*prospective cohort study
*intervention trial
Population 
Eligible individuals 
Consenting individuals 
Randomise 
        Intervention             Control group  
(Baseline measurements) 
 
Measure & compare outcomes 
Doing a 
randomised 
controlled 
trial
Look at :
Non-compliance
Completeness of 
follow-up
• Strengths
• Avoid bias related to confounding factors (through a control group)
• Selection bias (through randomization) 
• Interpretation bias (through double blinding).
• Weaknesses 
• Recruited patients in clinical trials and study experimental conditions 
markedly differ from the situation in real life. 
• Trials recruit a mix of good and poor responders, so that the average 
therapeutic response is most often mitigated.
• Ethics for performing some studies
Key issues in Randomized trails
• Uncertainty principle and clinical equipoise
• Randomization and confounder overlap
• Allocation concealment before trial
• Blinding   after trial starts
• Ethical Issues in an interventional study
• Study compliance and loss to follow up.
Why do doctors need to be able to critically 
appraise RCTs
• They are 
• Gold standard evidence for causation
• Gold standard assessment of effectiveness of treatment
• BUT:
• poorly conducted RCT may be biased and poorer evidence than 
observational study
• CANNOT assume just because a study is described as an RCT that 
the findings are unbiased
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